Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Ulotaront in Japanese Schizophrenia Patients
NCT04325737Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Mar 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ulotaront in schizophrenia (4 cohorts), sponsored by Sumitomo Pharma. Primary endpoint: Frequency of AEs, SAEs, and AEs resulting in discontinuation at 21 days. Started Mar 2020; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04325737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04325737.